B. Riley raised the firm’s price target on Lantheus to $99 from $95 and keeps a Buy rating on the shares. The analyst is increasingly positive on Pylarify’s growth in Q1 following Telix’s Q1 earnings report. The favorable trend of Telix’s Illuccix read positively to Pylarify, the analyst tells investors in a research note. The firm continues to view Lantheus as “best fitted for revenue-falling big pharma to acquire and take a leadership position in this emergent radiopharma space.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
- Lantheus director sells $6.13M in common stock
- Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
- Perspective Therapeutics acquires CGMP-compliant manufacturing facility
- Lantheus announces FDA approval of DEFINITY for pediatric patients